BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial

BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial

Source: 
Clinical Trials Arena
snippet: 

Asklepios BioPharmaceutical (AskBio) subsidiary BrainVectis has obtained clearance from the French National Agency for Safety of Medicines and Health Products (ANSM) to carry out the Phase I/II clinical trial of its new gene therapy, BV-101, for treating Huntington’s disease (HD).